Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group

Aristotle Bamias1*, Christos Papadimitriou1, Eleni Efstathiou1, Alexandros Rodolakis2, Georgios Vlahos2, Zannis Voulgaris2, Georgios Bozas1, Georgios Fountzilas3, Gerassimos Aravantinos4, Evagelia Razis5, Dimitra Gika1 and Meletios A Dimopoulos1

Author Affiliations

1 Department of Clinical Therapeutics, Medical School, University of Athens, Athens, Greece

2 First Department of Obstetrics and Gynaecology, Medical School, University of Athens, Athens, Greece

3 Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece

4 Third Medical Department, Agii Anargyri Hospital, Athens, Greece

5 Hygia Hospital, Athens, Greece

For all author emails, please log on.

BMC Cancer 2006, 6:228  doi:10.1186/1471-2407-6-228

Published: 25 September 2006

Abstract

Background

Surgery can cure a significant percentage of ovarian carcinoma confined to the pelvis. Nevertheless, there is still a 10–50% recurrence rate. We administered paclitaxel/carboplatin as adjuvant treatment in early-stage ovarian carcinoma.

Methods

Patients with stages Ia or Ib, Grade 2 or 3 and Ic to IIb (any grade) were included. Patients were treated with 4 cycles of Paclitaxel 175 mg/m2 and Carboplatin [area under the curve (AUC) 6 (Calvert Formula)] every 3 weeks.

Results

Sixty-nine patients with no residual disease following cytoreductive surgery and minimal or modified surgical staging were included in this analysis. Grade 3 or 4 neutropenia occured in 29.9% of patients, while neutropenic fever was reported in 4.5%. Neurotoxicity (all Grade 1 or 2) was reported in 50% of cases. Median follow-up was 62 months. 5-year overall survival (OS) and relapse-free survival (RFS) were: 87% (95% confidence intervals [CI]: 78–96) and 79% (95% CI: 69–89), respectively. Significantly fewer patients with stages Ic-IIb and tumor grade 2 or 3 achieved a 5-year RFS than patients with only one of these two factors (73% vs 92%, p = 0.03).

Conclusion

Paclitaxel/Carboplatin chemotherapy is a safe and effective adjuvant treatment in early-stage ovarian carcinoma. Patients with stages Ic-IIb and tumor grade 2 or 3 may benefit from more extensive treatment.